Nexalin Technology Inc (NXL)

$0.43 -0.01 (-1.21%)
Market Cap 8.87M
Revenue (ttm) 300,000.00
Net Income (ttm) -8.22M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -2,740.00%
Debt to Equity Ratio 0.00
Volume 234,300
Avg Vol 568,672
Day's Range N/A - N/A
Shares Out 20.58M
Stochastic %K 40%
Beta 4.18
Analysts Strong Sell
Price Target $2.00

Company Profile

Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. The company offers Generation 1, an easy-to-administer medical device which utilizes bioelectronic medical technology to treat anxiety, insomnia, and depression without the need for drugs or psychotherapy; and Generation 2 and Generation 3 headset devices for the treatment of depression, substance use disorder, traumatic brain injur...

Industry: Medical Devices
Sector: Healthcare
Phone: 832 260 0222
Address:
1776 Yorktown, Suite 550, Houston, United States
SporkGalaxy
SporkGalaxy Apr. 24 at 11:23 PM
$NXL heading into a good close
0 · Reply
MaskMaker
MaskMaker Apr. 24 at 8:18 AM
$NXL
0 · Reply
MaskMaker
MaskMaker Apr. 23 at 11:23 PM
$APCX $IGC $MPU $NXL $VTGN
0 · Reply
MaskMaker
MaskMaker Apr. 23 at 11:21 PM
$NXL
0 · Reply
Dante_s_Inferno
Dante_s_Inferno Apr. 23 at 6:27 PM
$NXL this stock is a joke lol
0 · Reply
MaskMaker
MaskMaker Apr. 23 at 5:22 PM
$NXL
1 · Reply
MaskMaker
MaskMaker Apr. 22 at 9:34 PM
$NXL
0 · Reply
focafoca99
focafoca99 Apr. 22 at 6:35 PM
$NXL its HALO Clarity pivotal trial is advancing toward enrollment in the second quarter of 2026.
0 · Reply
PAULSTOCK57
PAULSTOCK57 Apr. 22 at 12:58 PM
$NXL According to Mark White’s webinar, Nexalin plans to start selling its product this year, but FDA clearance isn’t expected before 2027. Does anyone know what their plan is?
0 · Reply
MaskMaker
MaskMaker Apr. 22 at 7:26 AM
$NXL
0 · Reply
Latest News on NXL
Nexalin Technology Advances Pivotal Clinical Trial of HALO™ Clarity Toward Q2 2026 Enrollment

Apr 22, 2026, 9:35 AM EDT - 3 days ago

Nexalin Technology Advances Pivotal Clinical Trial of HALO™ Clarity Toward Q2 2026 Enrollment

Nexalin Advances FDA Alzheimer's Strategy Following Landmark Leadership Meetings in the U.S. and China

Apr 15, 2026, 10:00 AM EDT - 10 days ago

Nexalin Advances FDA Alzheimer's Strategy Following Landmark Leadership Meetings in the U.S. and China

Join Nexalin's Exclusive Live Investor Webinar and Q&A Session on April 21

Apr 14, 2026, 8:30 AM EDT - 11 days ago

Join Nexalin's Exclusive Live Investor Webinar and Q&A Session on April 21

Nexalin Announces Peer-Reviewed Study Showing the Company's DIFS™ Technology Reduced Self-Injury and Depression Symptoms in Female Adolescents

Apr 9, 2026, 7:47 AM EDT - 16 days ago

Nexalin Announces Peer-Reviewed Study Showing the Company's DIFS™ Technology Reduced Self-Injury and Depression Symptoms in Female Adolescents

Nexalin Announces Pivotal HALO™ Clarity Trial to Support Planned De Novo FDA Submission Targeting Multi-Billion-Dollar Insomnia Market

Feb 24, 2026, 8:07 AM EST - 2 months ago

Nexalin Announces Pivotal HALO™ Clarity Trial to Support Planned De Novo FDA Submission Targeting Multi-Billion-Dollar Insomnia Market

Nexalin Participates in and Commends Recent Congressional Momentum Supporting Deep Brain Neurostimulation Research for Veterans and Neurological Disorders

Feb 23, 2026, 8:18 AM EST - 2 months ago

Nexalin Participates in and Commends Recent Congressional Momentum Supporting Deep Brain Neurostimulation Research for Veterans and Neurological Disorders

Nexalin Launches NeuroCare®, an AI-Driven Virtual Clinic Designed to Transform Access for Patients with Alzheimer's, Mood Disorders, TBI & PTSD Care

Feb 5, 2026, 8:37 AM EST - 2 months ago

Nexalin Launches NeuroCare®, an AI-Driven Virtual Clinic Designed to Transform Access for Patients with Alzheimer's, Mood Disorders, TBI & PTSD Care

Nexalin Highlights its Expanding Body of Peer-Reviewed Neuroimaging Research Confirming its DIFS™ Technology as the Leader in Evidenced-Based Non-Invasive Brain Stimulation

Feb 2, 2026, 8:45 AM EST - 2 months ago

Nexalin Highlights its Expanding Body of Peer-Reviewed Neuroimaging Research Confirming its DIFS™ Technology as the Leader in Evidenced-Based Non-Invasive Brain Stimulation

Published Peer-Reviewed Study Demonstrates Nexalin's DIFS™ Neurostimulation Improves Attention and Normalizes Brain Activity in Patients with ADHD

Jan 14, 2026, 9:00 AM EST - 3 months ago

Published Peer-Reviewed Study Demonstrates Nexalin's DIFS™ Neurostimulation Improves Attention and Normalizes Brain Activity in Patients with ADHD

Nexalin Technology Completes FDA Q-Submission Meeting for Gen-2 SYNC™ Neurostimulation Console in Alzheimer's Disease Program

Dec 3, 2025, 8:00 AM EST - 5 months ago

Nexalin Technology Completes FDA Q-Submission Meeting for Gen-2 SYNC™ Neurostimulation Console in Alzheimer's Disease Program

Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session on December 4

Dec 2, 2025, 8:00 AM EST - 5 months ago

Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session on December 4

Nexalin's 15 Milliamp Neurostimulation Device Demonstrates Promising Results in Treating Gambling Disorder with Alcohol Use Comorbidity

Nov 18, 2025, 9:00 AM EST - 5 months ago

Nexalin's 15 Milliamp Neurostimulation Device Demonstrates Promising Results in Treating Gambling Disorder with Alcohol Use Comorbidity

Nexalin Technology Appoints Carmi Masha Technologies Ltd. as Exclusive Distributor in Israel

Nov 13, 2025, 9:15 AM EST - 5 months ago

Nexalin Technology Appoints Carmi Masha Technologies Ltd. as Exclusive Distributor in Israel

Nexalin Technology's Q-Submission for Gen-2 SYNC Accepted by U.S. FDA for the Treatment of Alzheimer's Disease and Dementia

Nov 5, 2025, 8:30 AM EST - 6 months ago

Nexalin Technology's Q-Submission for Gen-2 SYNC Accepted by U.S. FDA for the Treatment of Alzheimer's Disease and Dementia

Nexalin Technology Announces Regulatory Approval to Sell Gen 2 SYNC, 15 mA Neurostimulation DIFS™ Device in Israel

Oct 30, 2025, 8:30 AM EDT - 6 months ago

Nexalin Technology Announces Regulatory Approval to Sell Gen 2 SYNC, 15 mA Neurostimulation DIFS™ Device in Israel

Nexalin's DIFS™ Neurostimulation Shows Cognitive and Brain Network Improvements in Alzheimer's and Dementia Across Three Peer-Reviewed Studies

Oct 21, 2025, 9:00 AM EDT - 6 months ago

Nexalin's DIFS™ Neurostimulation Shows Cognitive and Brain Network Improvements in Alzheimer's and Dementia Across Three Peer-Reviewed Studies

Nexalin Technology Expands Scientific Advisory Board with Appointment of Dr. Robert Rothstein to Support Alzheimer's and Traumatic Brain Injury Programs

Oct 13, 2025, 8:30 AM EDT - 6 months ago

Nexalin Technology Expands Scientific Advisory Board with Appointment of Dr. Robert Rothstein to Support Alzheimer's and Traumatic Brain Injury Programs

Nexalin Technology Announces Attendance at the 2025 Maxim Growth Summit

Oct 10, 2025, 8:00 AM EDT - 7 months ago

Nexalin Technology Announces Attendance at the 2025 Maxim Growth Summit

Why Is Micro-Cap Stock Nexalin Technology Rallying On Wednesday?

Oct 8, 2025, 2:45 PM EDT - 7 months ago

Why Is Micro-Cap Stock Nexalin Technology Rallying On Wednesday?

Nexalin Technology Announces Additional Positive Clinical Results in Alzheimer's Disease with Gen-2 SYNC Neurostimulation Device

Oct 8, 2025, 8:30 AM EDT - 7 months ago

Nexalin Technology Announces Additional Positive Clinical Results in Alzheimer's Disease with Gen-2 SYNC Neurostimulation Device

Nexalin Technology Announces Issuance of U.S. Patent Covering HALO™ Clarity Device Featuring DIFS™ Technology

Sep 25, 2025, 8:30 AM EDT - 7 months ago

Nexalin Technology Announces Issuance of U.S. Patent Covering HALO™ Clarity Device Featuring DIFS™ Technology

Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session on September 9

Aug 25, 2025, 9:00 AM EDT - 8 months ago

Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session on September 9

Nexalin Technology Appoints Highly Experienced Financial Leader Justin Van Fleet as CFO to Support Nexalin's Next Phase of Growth and Strategic Initiatives

Aug 1, 2025, 8:30 AM EDT - 9 months ago

Nexalin Technology Appoints Highly Experienced Financial Leader Justin Van Fleet as CFO to Support Nexalin's Next Phase of Growth and Strategic Initiatives

Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session on June 3

May 28, 2025, 10:00 AM EDT - 11 months ago

Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session on June 3

Nexalin Technology Reconstitutes Scientific Advisory Board with Leading Experts to Advance Alzheimer's Program Amid Encouraging Data

May 13, 2025, 8:30 AM EDT - 1 year ago

Nexalin Technology Reconstitutes Scientific Advisory Board with Leading Experts to Advance Alzheimer's Program Amid Encouraging Data

Nexalin Technology Announces Closing of Previously Announced $5.0 Million Underwritten Public Offering

May 6, 2025, 2:40 PM EDT - 1 year ago

Nexalin Technology Announces Closing of Previously Announced $5.0 Million Underwritten Public Offering

Nexalin Technology Announces Pricing of $5.0 Million Public Offering of Common Stock

May 5, 2025, 8:20 AM EDT - 1 year ago

Nexalin Technology Announces Pricing of $5.0 Million Public Offering of Common Stock

Nexalin Technology Initiates FDA Q-Submission Process for Gen-2 SYNC Following Encouraging Data and Preliminary FDA Feedback

May 1, 2025, 10:30 AM EDT - 1 year ago

Nexalin Technology Initiates FDA Q-Submission Process for Gen-2 SYNC Following Encouraging Data and Preliminary FDA Feedback

Nexalin Technology Receives IRB Approval in Brazil and Begins Clinical Trial for Anxiety and Insomnia

Apr 24, 2025, 9:00 AM EDT - 1 year ago

Nexalin Technology Receives IRB Approval in Brazil and Begins Clinical Trial for Anxiety and Insomnia

Nexalin Technology Announces Completion of Phases One Through Five of its Virtual Clinic and Digital Ecosystem for HALO™ Clinical Research and Patient Management

Apr 23, 2025, 9:15 AM EDT - 1 year ago

Nexalin Technology Announces Completion of Phases One Through Five of its Virtual Clinic and Digital Ecosystem for HALO™ Clinical Research and Patient Management

Nexalin Technology Expresses Strong Support for Health Tech Investment Act to Advance Medicare Reimbursement for AI-Enabled Devices

Apr 21, 2025, 8:00 AM EDT - 1 year ago

Nexalin Technology Expresses Strong Support for Health Tech Investment Act to Advance Medicare Reimbursement for AI-Enabled Devices

Nexalin Technology Secures USPTO Patent for Deep Intracranial Frequency Stimulation (DIFS™) Technology in Treating Substance Use Disorders

Apr 14, 2025, 12:30 PM EDT - 1 year ago

Nexalin Technology Secures USPTO Patent for Deep Intracranial Frequency Stimulation (DIFS™) Technology in Treating Substance Use Disorders

Nexalin Technology Enrolls First Patients and Advances Toward Treatment in UCSD Clinical Trial

Apr 2, 2025, 8:30 AM EDT - 1 year ago

Nexalin Technology Enrolls First Patients and Advances Toward Treatment in UCSD Clinical Trial

Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session on April 3

Mar 26, 2025, 8:30 AM EDT - 1 year ago

Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session on April 3

Nexalin Technology Receives Notice of Allowance from the USPTO for Patent Covering Deep Intracranial Frequency Stimulation (DIFS™) Technology for Opioid and Other Substance Use Disorders

Mar 3, 2025, 8:30 AM EST - 1 year ago

Nexalin Technology Receives Notice of Allowance from the USPTO for Patent Covering Deep Intracranial Frequency Stimulation (DIFS™) Technology for Opioid and Other Substance Use Disorders

Nexalin Technology Announces Initiation of Patient Recruitment for UCSD's TBI & PTSD Clinical Study Following IRB Approval

Feb 28, 2025, 8:30 AM EST - 1 year ago

Nexalin Technology Announces Initiation of Patient Recruitment for UCSD's TBI & PTSD Clinical Study Following IRB Approval

Nexalin Technology Welcomes General Wesley Clark to Military & Government Advisory Board

Feb 26, 2025, 8:30 AM EST - 1 year ago

Nexalin Technology Welcomes General Wesley Clark to Military & Government Advisory Board

Nexalin Technology Announces UCSD IRB Approval for use of HALO™ Clarity in Clinical Trials for mTBI and PTSD Treatment

Feb 18, 2025, 8:30 AM EST - 1 year ago

Nexalin Technology Announces UCSD IRB Approval for use of HALO™ Clarity in Clinical Trials for mTBI and PTSD Treatment

Nexalin Appointed as Industry Co-Chair of National TBI Registry Coalition

Feb 10, 2025, 9:00 AM EST - 1 year ago

Nexalin Appointed as Industry Co-Chair of National TBI Registry Coalition

Nexalin's Breakthrough DIFS™ Neurostimulation Device Demonstrates Reduction in Blood Pressure while Enhancing Mental Health According to New Landmark Study

Feb 3, 2025, 8:30 AM EST - 1 year ago

Nexalin's Breakthrough DIFS™ Neurostimulation Device Demonstrates Reduction in Blood Pressure while Enhancing Mental Health According to New Landmark Study

Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session, Today, January 23

Jan 23, 2025, 11:00 AM EST - 1 year ago

Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session, Today, January 23

Nexalin Technology Completes Phase 1of its Innovative Virtual Clinic

Dec 23, 2024, 10:00 AM EST - 1 year ago

Nexalin Technology Completes Phase 1of its Innovative Virtual Clinic

New Peer-Reviewed Publication Validates Nexalin's Deep Intracranial Frequency Stimulation (DIFS) Technology, Reinforcing Leadership in High-Growth Neuromodulation Market

Nov 26, 2024, 10:00 AM EST - 1 year ago

New Peer-Reviewed Publication Validates Nexalin's Deep Intracranial Frequency Stimulation (DIFS) Technology, Reinforcing Leadership in High-Growth Neuromodulation Market

Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session on November 5th

Nov 1, 2024, 2:00 PM EDT - 1 year ago

Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session on November 5th

Nexalin Technology Regains Compliance with Nasdaq Continued Listing Requirements

Nov 1, 2024, 10:34 AM EDT - 1 year ago

Nexalin Technology Regains Compliance with Nasdaq Continued Listing Requirements

LOBO EV and Nexalin Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Nov 1, 2024, 9:00 AM EDT - 1 year ago

LOBO EV and Nexalin Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

LOBO

Nexalin Technology Announces Landmark Study on Alzheimer's Disease and Deep Intracranial Frequency Stimulation Published in Journal of Alzheimer's Disease

Oct 28, 2024, 8:30 AM EDT - 1 year ago

Nexalin Technology Announces Landmark Study on Alzheimer's Disease and Deep Intracranial Frequency Stimulation Published in Journal of Alzheimer's Disease

Nexalin Technology and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Oct 25, 2024, 9:00 AM EDT - 1 year ago

Nexalin Technology and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

CLDI

Nexalin Technology Announces Planned Clinical Trial Utilizing Gen-3 Halo Headset in Partnership with UC San Diego & San Diego VA

Oct 22, 2024, 2:15 PM EDT - 1 year ago

Nexalin Technology Announces Planned Clinical Trial Utilizing Gen-3 Halo Headset in Partnership with UC San Diego & San Diego VA

New Study Shows Nexalin's Deep Intracranial Frequency Stimulation (DIFS) Significantly Improves Memory and Cognitive Function in Alzheimer's Patients

Oct 17, 2024, 8:30 AM EDT - 1 year ago

New Study Shows Nexalin's Deep Intracranial Frequency Stimulation (DIFS) Significantly Improves Memory and Cognitive Function in Alzheimer's Patients

SporkGalaxy
SporkGalaxy Apr. 24 at 11:23 PM
$NXL heading into a good close
0 · Reply
MaskMaker
MaskMaker Apr. 24 at 8:18 AM
$NXL
0 · Reply
MaskMaker
MaskMaker Apr. 23 at 11:23 PM
$APCX $IGC $MPU $NXL $VTGN
0 · Reply
MaskMaker
MaskMaker Apr. 23 at 11:21 PM
$NXL
0 · Reply
Dante_s_Inferno
Dante_s_Inferno Apr. 23 at 6:27 PM
$NXL this stock is a joke lol
0 · Reply
MaskMaker
MaskMaker Apr. 23 at 5:22 PM
$NXL
1 · Reply
MaskMaker
MaskMaker Apr. 22 at 9:34 PM
$NXL
0 · Reply
focafoca99
focafoca99 Apr. 22 at 6:35 PM
$NXL its HALO Clarity pivotal trial is advancing toward enrollment in the second quarter of 2026.
0 · Reply
PAULSTOCK57
PAULSTOCK57 Apr. 22 at 12:58 PM
$NXL According to Mark White’s webinar, Nexalin plans to start selling its product this year, but FDA clearance isn’t expected before 2027. Does anyone know what their plan is?
0 · Reply
MaskMaker
MaskMaker Apr. 22 at 7:26 AM
$NXL
0 · Reply
MaskMaker
MaskMaker Apr. 21 at 11:25 PM
$NXL
0 · Reply
peterpan124
peterpan124 Apr. 21 at 10:57 PM
$NXL question is when do they need to raise cash again?
0 · Reply
lessurml
lessurml Apr. 21 at 7:55 PM
$NXL bought some, good buy
0 · Reply
peterpan124
peterpan124 Apr. 21 at 5:12 PM
$NXL hello 👋 anybody here? Looking at opening position
0 · Reply
MaskMaker
MaskMaker Apr. 21 at 3:56 PM
$NXL
0 · Reply
MaskMaker
MaskMaker Apr. 20 at 10:52 PM
$NXL
0 · Reply
MaskMaker
MaskMaker Apr. 19 at 4:38 AM
$NXL
1 · Reply
MaskMaker
MaskMaker Apr. 18 at 6:46 AM
$NXL
0 · Reply
MaskMaker
MaskMaker Apr. 18 at 12:46 AM
$APCX $MPU $NNBR $NXL Great day for $APCX & $NNBR
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Apr. 17 at 10:58 PM
$NXL RSI: 68.62, MACD: 0.0049 Vol: 0.05, MA20: 0.40, MA50: 0.44 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
MaskMaker
MaskMaker Apr. 17 at 7:39 PM
$NXL
0 · Reply
MaskMaker
MaskMaker Apr. 17 at 5:09 AM
$NXL
0 · Reply